MedPath

Study on treatment of traditional Chinese medicine of drug-induced liver injury: a randomized controlled trial.

Phase 1
Recruiting
Conditions
Drug-induced liver injury
Registration Number
ITMCTR2000003269
Lead Sponsor
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Those who meet the diagnostic criteria for tuberculosis and have abnormal liver function after applying anti-tuberculosis drugs;
2. The severity of DILI is graded 1-2;
3. The age range is between 18-75 years old;
4. Not taking other drugs to protect liver and reduce enzyme, Or has been suspended for more than 2 weeks;
5. Signed informed consent voluntarily.

Exclusion Criteria

1. The liver function test before medication is elevated in alanine aminotransferase or bilirubin, and any of them is> 2 times the upper limit of normal value;
2. People with HIV infection, the original history of viral hepatitis or serological signs of hepatitis Those with positive substance;
3. Combined with serious primary diseases such as cardiocerebrovascular, kidney, hematopoietic system, peptic ulcer, or serious diseases (such as tumors) that affect their survival, or patients with mental or legal disabilities;
4. Do have a history of alcohol and drug abuse;
5. Allergic constitution, or known to be allergic to the drug components in the test protocol;
6. Pregnant, pregnant or lactating women.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
iver function;TCM syndrome points;Life quality assessment;
Secondary Outcome Measures
NameTimeMethod
Immune function test;Coagulation test;Renal function;
© Copyright 2025. All Rights Reserved by MedPath